FINALLY HARD FACT GOOD NEWS!
Stellar Biotech to provide KLH for BiovaxID treatment
Ticker Symbol: C:KLH
Stellar Biotech to provide KLH for BiovaxID treatment
Stellar Biotechnologies Inc (C:KLH)
Shares Issued 79,421,650
Last Close 10/22/2014 $1.39
Thursday October 23 2014 - News Release
Mr. Mark McPartland reports
STELLAR BIOTECHNOLOGIES AND BIOVEST INTERNATIONAL SIGN KLH SUPPLY AGREEMENT FOR BIOVAXID IMMUNOTHERAPY FOR FOLLICULAR NON-HODGKIN'S LYMPHOMA
Stellar Biotechnologies Inc. and Biovest International Inc. have executed a definitive supply agreement to meet Biovest's requirements for keyhole limpet hemocyanin (KLH) for use in Biovest's BiovaxID active immunotherapy to treat follicular non-Hodgkin's lymphoma.
Stellar is a leader in sustainable manufacture of KLH, an immune-stimulating protein widely used as a carrier molecule in active immunotherapy drugs in development for certain cancers and other diseases. Stellar manufactures its KLH products under the brand Stellar KLH.
Biovest is a biotechnology company developing and commercializing BiovaxIDtrademark (dasiprotimut-T), an active immunotherapy to treat follicular non-Hodgkin's lymphoma. BiovaxIDtrademark combines autologous heterohybridoma-derived tumor idiotype protein coupled to KLH as the carrier molecule. BiovaxIDtrademark has successfully completed Phase 2 and Phase 3 clinical trial development and is currently the subject of a Marketing Authorization Application (MAA) under review by the European Medicines Agency (EMA).
The purpose of the supply agreement is to establish the terms for the production and supply of Stellar KLH? to Biovest, for use as an active component in BiovaxIDtrademark immunotherapy vaccine in both commercial distribution as well as for future clinical trials.
The supply agreement requires Stellar to deliver Stellar KLH? to Biovest compliant with cGMP standards required for Biovest's ongoing development and as an anticipated commercial supply. Biovest is obligated to purchase Stellar KLH? at agreed forecasted quantities and prices. The supply agreement has an initial three-year term, which may be renewed by Biovest for additional one-year periods.
The supply agreement provides for Stellar and Biovest to consummate a separate quality agreement, within three months, to list the quality aspects and procedures relating to manufacture and release of the cGMP-compliant Stellar KLH?. Biovest will appoint Stellar as exclusive supplier of KLH in connection with the potential future commercialization of BiovaxIDtrademark, subject to negotiation and execution of commercial production and supply terms.
"Stellar's key growth initiative is to leverage our Stellar KLH? technology into multiple clinical pathways and the BiovaxIDtrademark program is a good example of the value of our core business for this purpose," said Frank Oakes, President and CEO of Stellar Biotechnologies, Inc. "There are many new KLH-based immunotherapies advancing in clinical trials and we are positioning Stellar to be the leading company capable of delivering the scalable, sustainable supplies of KLH that will be needed by these pharmaceutical pipelines."
"We are pleased to collaborate with Stellar Biotechnologies to continue the clinical progress of our active immunotherapy (BiovaxID) and are proud to work with Stellar in anticipation of our future commercial success," said Carlos Santos, Chief Executive Officer of Biovest. "BiovaxID immunotherapy has demonstrated ability in long-running clinical trials to elicit potent anti-tumor immune responses and extend remission duration in patients suffering from follicular non-Hodgkin's lymphoma. If approved, we anticipate that this product will offer an innovative adjuvant/consolidation vaccine strategy for patients with this disease."
About Biovest International, Inc.
Biovest International, Inc. is a pharmaceutical company focused in the field of active personalized immunotherapy development targeting life-threatening cancers of the blood system, marketing state-of-the-art bioreactors, and providing a full range of custom biomanufacturing services. Biovest's lead personalized cancer vaccine candidate BiovaxIDtrademark is an autologous active immunotherapy (personalized cancer vaccine) that targets follicular non-Hodgkin's lymphoma, mantle cell lymphoma, and potentially other B-cell malignancies. BiovaxIDtrademark has undergone three clinical trials conducted in collaboration with the U.S. National Cancer Institute (NCI) that have demonstrated BiovaxIDtrademark's ability to increase the duration of cancer remission following chemotherapy and to induce immune responses which correlate highly with long-term survival. Biovest is currently in the process of pursuing European marketing approval for BiovaxIDtrademark.
AI
